REGENOPIA – PROMISING NEW TREATMENT FOR DRY EYE DISEASE
DOI:
https://doi.org/10.61699/cjmps-v1-i2-3-p57-69Keywords:
dry eye disease, dry eye syndrome, treatment, Regenopia, sodium hyaluronate, trehalose, D-panthenolAbstract
Dry eye syndrome is one of the main problems of modern ophthalmological pathology. Although the treatment of dry eye syndrome has made great strides, the development of new treatments continues to be a major challenge for scientists and ophthalmologists around the world. The development of highly effective and safe eye drops is especially important. The aim of the article is to conduct research on new eyedrops called Regenopia – the unique combination of three active substances: sodium hyaluronate, trehalose, and D-panthenol in the treatment of DED. Clinical observation of 128 patients (256 eyes) (85 women and 43 men 18-60 years age group with DED (patients with any chronic or autoimmune diseases were excluded from the research) treated with Regenopia was conducted from February 1-st to May 30-th, 2023. DED was diagnosed by anamnesis and instrumental clinical investigations (Visometry, Biomicroscopy, Schirmer’s test, Tear Break up time (TBUT)). Moderate dry eye - 75% (192 eyes), severe dry eye - 25% (64 eyes). In 24 eyes Superficial Punctate Keratitis (SPK) was determined after examination of the epithelial layer of the cornea and conjunctiva. One drop of Regenopia was instilled 3 times a day in both eyes by patients (in cases of SPK complex method of treatment was prescribed) and patients were called for a repeat visit in 3 weeks and 6 weeks after the start of treatment. The condition was assessed using the same methods as at the time of diagnosis. The bioprotective, osmoprotective, regenerative properties of trehalose significantly enhance hyaluronic acid’s ability to provide effective hydration and long-term symptom relief along with the regenerative action of dexpanthenol. Using Regenopia significantly reduced the intensity of symptoms, increased the patient’s ability to work, and improved the quality of life, which allows us to recommend Regenopia as an effective, safe and reliable treatment for moderate to severe dry eye disease.
References
Murube J, Benítez del Castillo JM, Chenzhuo L, Berta A, Rolando M. The Madrid triple classification of dry eye. Arch Soc Esp Oftalmol. 2003;78(11):587-601.
Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J 1995;21(4):221-232.
Nelson JD, Craig JP, Akpek EK, et al. TFOS DEWS II Introduction. Ocul Surf. 2017;15(3):269-275. doi:10.1016/j.jtos.2017.05.005
Report of the international dry eye workshop (DEWS). Ocul Surf. 2007;5:65–204.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):75-92. doi:10.1016/s1542-0124(12)70081-2.
Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017; 15(3): 276-283.
Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, et al.TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3): 334- 365.
Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15(3): 539- 574.
Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15(3): 438-510.
Belmonte C, Nichols JJ, Cox SM, Brock JA, Begley CG, et al. TFOS DEWS II pain and sensation report. Ocul Surf. 2017;15(3): 404-437.
Willcox DP, Argüeso P, Georgiev GA, Holopainen JM, Laurie GW, et al. TFOS DEWS II tear film report. Ocul Surf . 2017;15(3): 366-403.
Sullivan DA, Rocha EM, Aragona P, Clayton JA, Ding J, et al. TFOS DEWS II sex, gender, and hormones report. Ocul Surf . 2017;15(3): 284-333.
Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, et al. TFOS DEWS II management and therapy report. Ocul Surf . 2017;15(3): 575-628.
Gomes JAP, Azar DT, Baudouin C, Efron N, Hirayama M, et al. TFOS DEWS II iatrogenic report. Ocul Surf . 2017;15(3): 511-538.
Novack GD, Asbell P, Barabino S, Bergamini VW, Ciolino JB, et al. TFOS DEWS II clinical trial design report. Ocul Surf. 2017; 15(3): 629-649.
Starr Christopher E., https://millennialeye.com/articles/2017-sept-oct/tfos-dews-ii-whats-new/
Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011;6(3):192-198
Tian YJ, Liu Y, Zou HD, Jiang YJ, Liang XQ, Sheng MJ, et al. Epidemiologic study of dry eye in populations equal or over 20 years old in Jiangning District of Shanghai. Zhonghua Yan Ke Za Zhi 2009;45:486e91.
Wegener AR, Meyer LM, Schonfeld CL. Effect of viscous agents on corneal density in dry eye disease. J Ocul Pharmacol Ther 2015;31(8):504-8.
Yu F, Liu X, Zhong Y, Guo X, Li M, Mao Z, et al. Sodium hyaluronate decreases ocular surface toxicity induced by benzalkonium chloride-preserved latanoprost: an in vivo study. Invest Ophthalmol Vis Sci 2013;54:3385-93.
Rah MJ. A review of hyaluronan and its ophthalmic applications. Optometry 2011;82(1):38-43.
Ho WT, Chiang TH, Chang SW, Chen YH, Hu FR, Wang IJ. Enhanced corneal wound healing with hyaluronic acid and high-potassium artificial tears. Clin Exp Optom 2013;96(6):536-541.
Troiano P, Monaco G. Effect of hypotonic 0.4% hyaluronic acid drops in dry eye patients: a cross-over study. Cornea 2008;27(10):1126-1130.
Baeyens V, Bron A, Baudouin C, Vismed/Hylovis Study Group. Efficacy of 0.18% hypotonic sodium hyaluronate ophthalmic solution in the treatment of signs and symptoms of dry eye disease. J Fr Ophtalmol 2012;35(6):412-9.
Chiambaretta F, Doan S, Labetoulle M, et al. A randomized, controlled study of the efficacy and safety of a new eyedrop formulation for moderate to severe dry eye syndrome. Eur J Ophthalmol. 2017;27(1):1-9. doi:10.5301/ejo.5000836.
Stoddard AR, Koetje LR, Mitchell AK, Schotanus MP, Ubels JL. Bioavailability of antioxidants applied to stratified human corneal epithelial cells. J Ocul Pharmacol Ther. 2013 Sep;29(7):681-7. doi: 10.1089/jop.2013.0014. Epub 2013 May 2. PMID: 23634787.
Hamdi IM. Effect of D-Panthenol on Corneal Epithelial Healing after Surface Laser Ablation. J Ophthalmol. 2018;2018:6537413. Published 2018 Nov 12. doi:10.1155/2018/6537413
Göbbels M, Gross D. Klinische Studie zur Wirksamkeit eines dexpanthenolhaltigen Tränenersatzmittels (Siccaprotect) bei der Behandlung Trockener Augen [Clinical study of the effectiveness of a dexpanthenol containing artificial tears solution (Siccaprotect) in treatment of dry eyes]. Klin Monbl Augenheilkd. 1996;209(2-3):84-88. doi:10.1055/s-2008-1035283
